FindTrial
Sign In

DCEMRI and DWI in early diagnosis of breast caner and evaluation, prognosis with neoadjuvant chemotherapy

DCEMRI and DWI in early diagnosis of breast caner and evaluation, prognosis with neoadjuvant chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017797
Enrollment
Unknown
Registered
2018-08-15
Start date
2015-04-15
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard: Histology or biopasy
Index test:DCEMRI&#32
pharmacokinetic&#32
parameters

Sponsors

LiaoNing Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Histology or biopasy proven breast cancer, and conform either with AJCC early stage breast cancer or AJCC advanced stage breast cancer; 2. Patients could provide informed consent, and could be reached in follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients were in pregnancy or lactation period; 2. No accurate histology results could be obtained; 3. could not be reached within 3 months after enrollment; 4. contradiction to MRI examinations; 5. With severe complications, e.g. renal insufficiency, cardiac malfunction; severe allergy to Gd.

Design outcomes

Primary

MeasureTime frame
DCEMRI pharmacokinetic parameters;DWI;breast lesion types and BIRADS;—

Countries

China

Contacts

Public ContactYahong Luo

LiaoNing Cancer Hospital

LuoYaHong8888@hotmail.com+86 18900917777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026